Medical physics

KORTUC Inc. Closed Financing From AXA Japan to Accelerate Pivotal Phase II Study of Novel Radiosensitizer for Cancer Radiotherapy

Retrieved on: 
Thursday, July 29, 2021

Today KORTUC Inc. , a Japanese clinical-stage biopharmaceutical company focusing on the clinical and product development of a novel radiosensitizer improving the effectiveness of cancer radiotherapy (RT), announces the closing of an equity investment from AXA Japan.

Key Points: 
  • Today KORTUC Inc. , a Japanese clinical-stage biopharmaceutical company focusing on the clinical and product development of a novel radiosensitizer improving the effectiveness of cancer radiotherapy (RT), announces the closing of an equity investment from AXA Japan.
  • KORTUC will use the financing to fund Research and Development activities, accelerate its Pivotal Phase II Study in the UK and pursue additional Pivotal Studies in the US.
  • Currently ongoing Pivotal Phase II Study focuses on application of Kortuc radiosensitizer to locally advanced/recurrent breast cancer patients undergoing RT.

Most Hospitals in The U.S. Plan to Buy an X-Ray System, Says Report

Retrieved on: 
Friday, July 30, 2021

This can be both an opportunity and a concern for watchers of the X-ray imaging market, according to IMV's report.

Key Points: 
  • This can be both an opportunity and a concern for watchers of the X-ray imaging market, according to IMV's report.
  • Almost two thirds of the hospitals "Yes" and "Maybe" plan to acquire fixed x-ray systems (primarily DR) and/or DR detector retrofit kits for their main radiology department over the next three years.
  • The report breaks out whether the need is new systems outright, retrofit systems or both.
  • The report also breaks out what size hospital answered in what ways, and which manufacturers customers will buy from.

Radiaction Medical Ltd. Secures Additional Patents in US and Japan - En-Route to Commercialization of its Radiation Shielding Technology

Retrieved on: 
Wednesday, July 28, 2021

Radiaction, is revolutionizing radiation protection by providing full-body shielding to all medical personnel during fluoroscopy-guided procedures.

Key Points: 
  • Radiaction, is revolutionizing radiation protection by providing full-body shielding to all medical personnel during fluoroscopy-guided procedures.
  • Mounted on the C-Arm, it encapsulates the imaging beam and blocks the scattered radiation at its origin, creating a paradigm shift in medical staff radiation protection.
  • The system will initially be offered to the Interventional Cardiology (IC) and Electrophysiology (EP) markets, where physicians experience the highest radiation exposure.
  • Radiaction has been expanding its IP assets continuously, protecting key technology developments for the radiation shielding device.

Radiaction Medical Ltd. Secures Additional Patents in US and Japan - En-Route to Commercialization of its Radiation Shielding Technology

Retrieved on: 
Wednesday, July 28, 2021

Radiaction, is revolutionizing radiation protection by providing full-body shielding to all medical personnel during fluoroscopy-guided procedures.

Key Points: 
  • Radiaction, is revolutionizing radiation protection by providing full-body shielding to all medical personnel during fluoroscopy-guided procedures.
  • Mounted on the C-Arm, it encapsulates the imaging beam and blocks the scattered radiation at its origin, creating a paradigm shift in medical staff radiation protection.
  • The system will initially be offered to the Interventional Cardiology (IC) and Electrophysiology (EP) markets, where physicians experience the highest radiation exposure.
  • Radiaction has been expanding its IP assets continuously, protecting key technology developments for the radiation shielding device.

neuro42 Announces the Closing of $6.5M Series A Round

Retrieved on: 
Tuesday, July 27, 2021

neuro42 , the medical technology company leading the next evolution of MRI and robotics, today announced the close of a $6.5M Series A financing round.

Key Points: 
  • neuro42 , the medical technology company leading the next evolution of MRI and robotics, today announced the close of a $6.5M Series A financing round.
  • Zepp Health led the financing round and is joined by ShangBay Capital and prominent angel investors, Krishna R. Bhupal and Philip Dolan.
  • To date, the Company has raised $7.8M of which $1.3M was in an oversubscribed seed round that closed earlier this year.
  • neuro42, Inc. is a San Francisco, CA based medical technology company focused on diagnostic imaging and image guided surgical interventions of the brain.

Clinical Trial Imaging Market worth $1.4 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, July 27, 2021

The services segment accounted for the largest share of the market, by product and service segment, in 2020

Key Points: 
  • The services segment accounted for the largest share of the market, by product and service segment, in 2020
    Based on product and service, the clinical trial imaging market is segmented into services and software.
  • The clinical trial imaging market is segmented into computed tomography, magnetic resonance imaging, ultrasound, positron emission tomography, X-ray, echocardiography and other modalities.
  • The major players operating in this clinical trial imaging market are ICON plc.
  • (US), anagram 4 clinical trials (Spain), Lyscaut Medical Imaging Company (Belgium), Calyx Group (UK), Bioseptive Inc. (Canada), ProScan Imaging LLC.

Clinical Trial Imaging Market worth $1.4 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, July 27, 2021

The services segment accounted for the largest share of the market, by product and service segment, in 2020

Key Points: 
  • The services segment accounted for the largest share of the market, by product and service segment, in 2020
    Based on product and service, the clinical trial imaging market is segmented into services and software.
  • The clinical trial imaging market is segmented into computed tomography, magnetic resonance imaging, ultrasound, positron emission tomography, X-ray, echocardiography and other modalities.
  • The major players operating in this clinical trial imaging market are ICON plc.
  • (US), anagram 4 clinical trials (Spain), Lyscaut Medical Imaging Company (Belgium), Calyx Group (UK), Bioseptive Inc. (Canada), ProScan Imaging LLC.

SimonMed Imaging Enhances Patient Services, Saves Millions in Voice and SMS Costs and Enables Future Growth with CPaaS Solution from IntelePeer

Retrieved on: 
Monday, July 26, 2021

We selected IntelePeer for their impressive track record and expertise, says SimonMed CIO Duleep Wikramanayke.

Key Points: 
  • We selected IntelePeer for their impressive track record and expertise, says SimonMed CIO Duleep Wikramanayke.
  • The companys solutions not only improve processes but also help in keeping overhead as low as possible.
  • Before implementation, SimonMeds voice and data costs totaled approximately $5.4 million.
  • SimonMed Imaging is the largest physician owned outpatient radiology practice in the United States and specializes in all major medical fields of medical imaging.

David K. Roemer, PhD, Celebrated for Excellence in Education and Theology

Retrieved on: 
Monday, July 26, 2021

Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

Key Points: 
  • Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
  • In 1972, he was recruited by Litton Medical Systems as a manager of radiation therapy products.
  • Throughout the following five years, he provided technical and sale support for radiation therapy equipment that had been manufactured by Toshiba Corporation.
  • While working for Siemens AG, he completed his education by earning a Master of Business Administration from Pace University's Lubin School of Business.

GenesisCare extends U.S. brachytherapy service with 27 Elekta Flexitron treatment devices

Retrieved on: 
Friday, July 23, 2021

ATLANTA, July 23, 2021 /PRNewswire/ --Elekta (EKTA-B.ST) announced today that GenesisCare , a leading global provider of integrated cancer care, has ordered 27 Flexitron brachytherapy afterloader systems, including service agreements.

Key Points: 
  • ATLANTA, July 23, 2021 /PRNewswire/ --Elekta (EKTA-B.ST) announced today that GenesisCare , a leading global provider of integrated cancer care, has ordered 27 Flexitron brachytherapy afterloader systems, including service agreements.
  • The cancer treatment devices will allow GenesisCare to continue to invest in the latest world-class technology while providing access to high-quality care to their patients throughout their U.S. centers.
  • Flexitron is Elekta's high dose rate (HDR) afterloader, used in almost two-thirds of all brachytherapy centers worldwide in over 100 countries.
  • The latest version of Flexitron, introduced in 2020, sets itself apart from conventional brachytherapy devices through its design, ensuring efficient, safe and effective treatments with fewer manual steps.